Skip to main
EXEL
EXEL logo

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 26%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. is poised for growth as its flagship molecule, cabozantinib, maintains its position as a leading treatment for renal cell carcinoma (RCC), bolstered by robust long-term data and recent label expansions into neuroendocrine tumors (NETs). The encouraging performance of zanzalintinib in combination with atezolizumab demonstrates statistically significant improvements in overall survival, enhancing the outlook for this asset as it gains traction in the market. As Exelixis continues to build on its successes and explore new indications, the overall positive trajectory of its products fosters a favorable investment sentiment in the biopharmaceutical sector.

Bears say

Exelixis Inc. is facing significant financial challenges, particularly with the anticipated 80% revenue decline by 2032 due to the impending patent expiration in 2031, which contrasts sharply with the market's more optimistic expectation of a 68% decline. The company also encounters competitive risks that could further jeopardize its market position, including potential erosion of market share for its primary drug, cabozantinib, across various oncology indications and disappointing data from its pipeline programs. Additionally, there are considerable developmental risks associated with its other treatments, notably zanzalintinib, which contribute to a cautious outlook on the company's financial prospects.

Exelixis (EXEL) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 26% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 19 analysts, Exelixis (EXEL) has a Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.